MedMira Inc MIR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MIR is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- CAD 0.08
- Day Range
- CAD 0.08–0.08
- 52-Week Range
- CAD 0.08–0.14
- Bid/Ask
- CAD 0.08 / CAD 0.08
- Market Cap
- CAD 52.63 Mil
- Volume/Avg
- 71,001 / 49,532
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 136.99
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- https://www.medmira.com
Valuation
|
Metric
|
MIR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 136.99 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MIR
|
|---|---|
Quick Ratio | 0.13 |
Current Ratio | 0.15 |
Interest Coverage | −1.82 |
Quick Ratio
MIR
Profitability
|
Metric
|
MIR
|
|---|---|
Return on Assets (Normalized) | −72.17% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
MIR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Kkyzclyqd | Pjwl | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pkcgdbpz | Ssgbwr | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wxnkzhpx | Hqyxnm | $98.1 Bil | |
MRNA
| Moderna Inc | Cxfhtkpp | Xvcn | $39.1 Bil | |
ARGX
| argenx SE ADR | Zjrpthkjn | Yvgr | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Thpfcpxw | Pxqq | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vsrkynkdk | Khlyx | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ntrdmdcv | Xjmkxd | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xcpjbtkcr | Whymy | $12.5 Bil | |
INCY
| Incyte Corp | Kzdpddztb | Kpgys | $11.9 Bil |